Tuberculosis (TB) continues to be a major global public health concern, requiring effective and accessible treatment options to combat the disease and reduce transmission. Key active pharmaceutical ingredients such as **Pyrazinamide** and **Ethambutol** remain essential components of first-line anti-tuberculosis therapy, contributing significantly to treatment success and patient recovery. Building on more than 50 years of pharmaceutical manufacturing expertise, Zhejiang Haizhou Pharmaceutical supplies high-quality intermediates and pharmaceutical solutions that support the production of critical anti-TB medications. With advanced manufacturing facilities, stringent quality management systems, and international regulatory approvals including NMPA, US FDA, and EDQM, Haizhou Pharm is committed to helping pharmaceutical partners deliver safe, reliable, and effective tuberculosis treatments worldwide, supporting global efforts to improve public health and disease control.